^
Association details:
| Biomarker: | EGFR overexpression |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) + Xtandi (enzalutamide capsule) (Androgen receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR-A Potential Therapeutic Target
Published date:
10/11/2021
Excerpt:
Afatinib or MK2206 combination therapy with the AR antagonist enzalutamide in the EGFR and EGFRvIII-overexpressing cells had synergistic efficacy. Our findings suggest that EGFR signaling is involved in AR activation in glioblastoma and buttresses the concept of combining an EGFR signaling inhibitor with AR antagonists as a potential glioblastoma treatment.
DOI:
10.3390/ijms222010954
